Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide in Inoperable or Metastatic Merkel Cell Carcinoma
NCT02351128Phase 2Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Apr 2015
- Primary completion
- May 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in Merkel cell carcinoma (MCC), sponsored by CHU Grenoble Alpes. Primary endpoint: Positive Response Rate at 3 months. Started Apr 2015; status: completed.
02
Drugs
lanreotide
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT02351128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351128.